Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC
This enduring activity will review clinical trial data on the efficacy and safety of monoclonal antibodies and vaccines authorized for use in the treatment and prevention of COVID-19, and highlight and address healthcare disparities during the COVID-19 pandemic.
This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists who treat and manage underserved patient populations.
Upon the completion of this program, attendees should be able to:
- Evaluate clinical trial data of vaccines and monoclonal antibody therapies for the prevention and treatment of COVID-19.
- Select appropriate treatment for managing mild-to-moderate COVID-19 for people with certain pre-existing conditions.
- Explain the efficacy and safety of approved vaccinations and monoclonal antibody treatments to patients
- Incorporate tools and resources developed to promote safe and responsible use of infusion therapies for the treatment of patients with COVID-19.
- Explain COVID-19 related initiatives and programs aimed at lessening health disparities in underserved communities.
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this online activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the online activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19. Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Shyama Kottilil, MD, PhD Discloses that the University of Maryland has received funds to participate in clinical trials, and he has received research funds paid to the university from Merck, Gilead Sciences, and Arbutus Biopharma. He has served on the advisory boards of Merck Inc and Regeneron Pharmaceuticals.
William A. Fischer II, MD Discloses that he has been contracted for research for Ridgeback Biopharmaceuticals for COVID-19 research, as well as consulted for Merck and Roche. He also worked for Syneos and Janssen for adjudication of AE in RSV and influenza studies respectively, and served as the site PI for the Phase I Lilly study of bamlanivimab and for the Phase II study of casirivimab/imdevimab at University of North Carolina.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this online activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the web-based activity.
- Submit the evaluation form to Med Learning Group.
You will receive your certificate upon completion.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
RELEASE DATE: October 08, 2021
EXPIRATION DATE: October 08, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.